Dermata raises ~$6.2M via warrant exercise at reduced price; issues new warrants

Dermata Therapeutics, Inc.

4,834,470 existing warrants exercised at reduced price of $1.284/share, yielding $6.2M gross proceeds.
New Series A warrants (5-year term) and Series B warrants (18-month term) issued, each exercisable at $1.284.
New warrants require shareholder approval per Nasdaq Rule 5635(d); exercise limited to 4.99% (or 9.99%) ownership.
H.C. Wainwright acted as exclusive financial advisor; fees include 7% cash plus 338,412 HCW warrants at $1.605.
Company plans to use net proceeds for general corporate purposes including R&D and clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.